Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 72

1.

Immune tolerance to tumor antigens occurs in a specialized environment of the spleen.

Ugel S, Peranzoni E, Desantis G, Chioda M, Walter S, Weinschenk T, Ochando JC, Cabrelle A, Mandruzzato S, Bronte V.

Cell Rep. 2012 Sep 27;2(3):628-39. doi: 10.1016/j.celrep.2012.08.006. Epub 2012 Sep 6.

2.

Signaling defects in anti-tumor T cells.

Frey AB, Monu N.

Immunol Rev. 2008 Apr;222:192-205. doi: 10.1111/j.1600-065X.2008.00606.x. Review.

4.

Targeting molecular and cellular inhibitory mechanisms for improvement of antitumor memory responses reactivated by tumor cell vaccine.

Webster WS, Thompson RH, Harris KJ, Frigola X, Kuntz S, Inman BA, Dong H.

J Immunol. 2007 Sep 1;179(5):2860-9.

5.

Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma.

Mortarini R, Piris A, Maurichi A, Molla A, Bersani I, Bono A, Bartoli C, Santinami M, Lombardo C, Ravagnani F, Cascinelli N, Parmiani G, Anichini A.

Cancer Res. 2003 May 15;63(10):2535-45.

6.

The lung vascular filter as a site of immune induction for T cell responses to large embolic antigen.

Willart MA, Jan de Heer H, Hammad H, Soullié T, Deswarte K, Clausen BE, Boon L, Hoogsteden HC, Lambrecht BN.

J Exp Med. 2009 Nov 23;206(12):2823-35. doi: 10.1084/jem.20082401. Epub 2009 Oct 26.

7.

Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery.

Schnurr M, Chen Q, Shin A, Chen W, Toy T, Jenderek C, Green S, Miloradovic L, Drane D, Davis ID, Villadangos J, Shortman K, Maraskovsky E, Cebon J.

Blood. 2005 Mar 15;105(6):2465-72. Epub 2004 Nov 16.

8.

Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.

Palucka AK, Ueno H, Connolly J, Kerneis-Norvell F, Blanck JP, Johnston DA, Fay J, Banchereau J.

J Immunother. 2006 Sep-Oct;29(5):545-57.

PMID:
16971810
9.

Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.

Sorensen MR, Holst PJ, Pircher H, Christensen JP, Thomsen AR.

Eur J Immunol. 2009 Oct;39(10):2725-36. doi: 10.1002/eji.200939543.

10.

In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma.

Wu A, Oh S, Gharagozlou S, Vedi RN, Ericson K, Low WC, Chen W, Ohlfest JR.

J Immunother. 2007 Nov-Dec;30(8):789-97.

PMID:
18049330
11.
12.

Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells.

Gabrilovich DI, Velders MP, Sotomayor EM, Kast WM.

J Immunol. 2001 May 1;166(9):5398-406.

13.

Characterization of the class I-restricted gp100 melanoma peptide-stimulated primary immune response in tumor-free vaccine-draining lymph nodes and peripheral blood.

Walker EB, Miller W, Haley D, Floyd K, Curti B, Urba WJ.

Clin Cancer Res. 2009 Apr 1;15(7):2541-51. doi: 10.1158/1078-0432.CCR-08-2806. Epub 2009 Mar 24.

14.

Peptide vaccine induces enhanced tumor growth associated with apoptosis induction in CD8+ T cells.

Muraoka D, Kato T, Wang L, Maeda Y, Noguchi T, Harada N, Takeda K, Yagita H, Guillaume P, Luescher I, Old LJ, Shiku H, Nishikawa H.

J Immunol. 2010 Sep 15;185(6):3768-76. doi: 10.4049/jimmunol.0903649. Epub 2010 Aug 23.

15.

Ex vivo characterization of multiepitopic tumor-specific CD8 T cells in patients with chronic myeloid leukemia: implications for vaccine development and adoptive cellular immunotherapy.

Gannagé M, Abel M, Michallet AS, Delluc S, Lambert M, Giraudier S, Kratzer R, Niedermann G, Saveanu L, Guilhot F, Camoin L, Varet B, Buzyn A, Caillat-Zucman S.

J Immunol. 2005 Jun 15;174(12):8210-8.

17.

CD8 cell division maintaining cytotoxic memory occurs predominantly in the bone marrow.

Parretta E, Cassese G, Barba P, Santoni A, Guardiola J, Di Rosa F.

J Immunol. 2005 Jun 15;174(12):7654-64.

19.

Predicting tumor outcome following cancer vaccination by monitoring quantitative and qualitative CD8+ T cell parameters.

Rosato A, Zoso A, Dalla Santa S, Milan G, Del Bianco P, De Salvo GL, Zanovello P.

J Immunol. 2006 Feb 1;176(3):1999-2006.

20.

A CCR4 antagonist combined with vaccines induces antigen-specific CD8+ T cells and tumor immunity against self antigens.

Pere H, Montier Y, Bayry J, Quintin-Colonna F, Merillon N, Dransart E, Badoual C, Gey A, Ravel P, Marcheteau E, Batteux F, Sandoval F, Adotevi O, Chiu C, Garcia S, Tanchot C, Lone YC, Ferreira LC, Nelson BH, Hanahan D, Fridman WH, Johannes L, Tartour E.

Blood. 2011 Nov 3;118(18):4853-62. doi: 10.1182/blood-2011-01-329656. Epub 2011 Sep 9.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk